UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Relation of titers of antibodies to CMV in blood donors to the transmission of cytomegalovirus infection

The Journal of infectious diseases, 1984-12, Vol.150 (6), p.883-888

1984

Volltextzugriff (PDF)

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

The New England journal of medicine, 2015-08, Vol.373 (8), p.714-725

2015

Volltextzugriff (PDF)

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

The New England journal of medicine, 2023-08, Vol.389 (8), p.687-699

2023

Volltextzugriff (PDF)

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

Clinical infectious diseases, 2023-08, Vol.77 (4), p.560-564

2023

Volltextzugriff (PDF)

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

The New England journal of medicine, 2011-10, Vol.365 (16), p.1482-1491

2011

Volltextzugriff (PDF)

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

Clinical infectious diseases, 2015-06, Vol.60 (12), p.1842-1851

2015

Volltextzugriff (PDF)

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

The Lancet infectious diseases, 2013-07, Vol.13 (7), p.587-596

2013

Volltextzugriff (PDF)

Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

AIDS (London), 2011-11, Vol.25 (17), p.2113-2122

2011

Volltextzugriff (PDF)

Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

Journal of hepatology, 2017, Vol.66 (1), p.S85-S85

2017

Volltextzugriff (PDF)

C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

Journal of hepatology, 2016, Vol.64 (2), p.S771-S771

2016

Volltextzugriff (PDF)

Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S1058-S1059

2017

Volltextzugriff (PDF)

Household ventilation and tuberculosis transmission in Kampala, Uganda

The international journal of tuberculosis and lung disease, 2013-06, Vol.17 (6), p.764-770

2013

Volltextzugriff (PDF)

PS-159 - Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

Journal of hepatology, 2017, Vol.66 (1), p.S85-S85

2017

Volltextzugriff (PDF)

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2

Open forum infectious diseases, 2017-06, Vol.4 (3), p.ofx154-ofx154

2017

Volltextzugriff (PDF)

SAT-163 - C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

Journal of hepatology, 2016, Vol.64 (2), p.S771-S771

2016

Volltextzugriff (PDF)

Risk of COVID-19 after natural infection or vaccinationResearch in context

EBioMedicine, 2023-10, Vol.96, p.104799

2023

Volltextzugriff (PDF)

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

Journal of Virus Eradication, 2017-08, Vol.3, p.8

2017

Volltextzugriff (PDF)

A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)

Journal of the Canadian Association of Gastroenterology, 2018-03, Vol.1 (suppl_1), p.299-300

2018

Volltextzugriff (PDF)

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap

American journal of respiratory and critical care medicine, 2011, Vol.184 (8), p.972-979

2011

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

ThemaClinical Trials

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(20)
Tagungsberichte
(1)

Sprache

Englisch
(21)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(11)
Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Infectious Diseases
(9)
Female
(7)
Hiv Infections - Drug Therapy
(7)
Male
(7)
Adult
(6)
Biological And Medical Sciences
(6)
Human Immunodeficiency Virus
(6)
Immunology
(6)
Hiv
(5)
Medical Sciences
(5)
Microbiology
(5)
Middle Aged
(5)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(4)
Antiretroviral Drugs
(4)
Antiretroviral Therapy
(4)
Antiviral Agents
(4)
Cd4 Lymphocyte Count
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Relation of titers of antibodies to CMV in blood donors to the transmission of cytomegalovirus infection

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir

Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study

Household ventilation and tuberculosis transmission in Kampala, Uganda

PS-159 - Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2

SAT-163 - C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

Risk of COVID-19 after natural infection or vaccinationResearch in context

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)

CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap

Aktive Filter

Suchergebnisse filtern